Ladiratuzumab vedotin

N/A

Report date: 2024/02/05 13:55:57

Base Information

Drug NameLadiratuzumab vedotin
Drug Alias NamehLIV22-vcMMAESGN-LIV1AMK-6440MK6440
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsAnti-LIV-1
TargetsZinc transporter ZIP6Tubulin
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsProstatic Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanItaly +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSeagen IncMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesSeagen IncPfizer IncMerck Sharp & Dohme LLC
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerTriple Negative Breast NeoplasmsBreast Neoplasms
Inactive IndicationsGastroesophageal Junction NeoplasmsProstatic NeoplasmsSmall Cell Lung Carcinoma +[8] 

Other Information

ATC CodeN/A
Related LinksN/A